Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service by Nightingale, Rebecca et al.
  1Nightingale R, et al. BMJ Open Resp Res 2020;7:e000639. doi:10.1136/bmjresp-2020-000639
To cite: Nightingale R, 
Nwosu N, Kutubudin F, et al. 
Is continuous positive airway 
pressure (CPAP) a new 
standard of care for type 1 
respiratory failure in COVID-19 
patients? A retrospective 
observational study of a 
dedicated COVID-19 CPAP 
service. BMJ Open Resp Res 
2020;7:e000639. doi:10.1136/
bmjresp-2020-000639
RN and NN are joint first 
authors.
Received 15 May 2020
Revised 18 June 2020
Accepted 23 June 2020
For numbered affiliations see 
end of article.
Correspondence to
Mrs Rebecca Nightingale;  
 rebecca. nightingale@ lstmed. 
ac. uk
Is continuous positive airway pressure 
(CPAP) a new standard of care for type 1 
respiratory failure in COVID-19 
patients? A retrospective observational 
study of a dedicated COVID-19 
CPAP service
Rebecca Nightingale   ,1,2 Nneka Nwosu,2 Farheen Kutubudin,2 Tom Fletcher,1,2 
Joe Lewis,1,2,3 Frederick Frost,2,3 Kathryn Haigh,2 Ryan Robinson,1,2 
Ayesha Kumar,2 Gareth Jones,2 Deborah Brown,2 Michael Abouyannis,1,2,3 
Mike Beadsworth,1,2 Peter Hampshire,2 Stephen Aston,2,3 Manish Gautam,2 
Hassan Burhan2
Perspective
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
The aim of this case series is to describe and evaluate 
our experience of continuous positive airway pressure 
(CPAP) to treat type 1 respiratory failure in patients with 
COVID-19. CPAP was delivered in negative pressure rooms 
in the newly repurposed infectious disease unit. We report 
a cohort of 24 patients with type 1 respiratory failure 
and COVID-19 admitted to the Royal Liverpool Hospital 
between 1 April and 30 April 2020. Overall, our results 
were positive; we were able to safely administer CPAP 
outside the walls of a critical care or high dependency 
unit environment and over half of patients (58%) avoided 
mechanical ventilation and a total of 19 out of 24 (79%) 
have survived and been discharged from our care.
INTRODUCTION
To date, there have been over 10 million 
confirmed cases of COVID-19 worldwide. It 
is thought that 5% of cases become seriously 
unwell, and of these, 20%–30% require crit-
ical care support.1 Continuous positive airway 
pressure (CPAP) is a potential supportive 
treatment for patients in type 1 respiratory 
failure, and despite initial concerns regarding 
its use in COVID-19, including the risk of 
lung barotrauma and increased SARS- CoV-2 
aerosolisation, early anecdotal experience 
has been favourable with newer guidelines 
now suggesting CPAP as an option for care.1–7 
NHS England guidelines now recommend its 
use while acknowledging the lack of evidence 
for efficacy.8 To address this knowledge gap, 
we present here our experience to date of 
CPAP use during the COVID-19 outbreak in 
Liverpool, UK.
METHODS
In late March 2020, one of the isolation wards 
in the Tropical and Infectious Disease Unit 
at the Liverpool University Hospitals NHS 
Foundation Trust was repurposed as a CPAP/
COVID-19 unit. CPAP was delivered in nega-
tive pressure single rooms with newly installed 
continuous non- invasive monitoring that was 
visible from outside the rooms. Negative pres-
sure capacity was rapidly increased using an 
innovative approach developed in the South 
Korean COVID-19 outbreak with indus-
trial HEPA filtered air purifying units that 
vent externally to create 10–15 air changes 
per hour. Staff wore appropriate personal 
protective equipment (PPE) as recom-
mended for aerosol generating procedures 
by Public Health England (this included 
the use of FFP3 masks) and completed 
competencies in donning and doffing PPE 
before being involved with patient care. To 
reduce oxygen demands at the hospital and 
to limit the amount of new equipment staff 
required training for, standard electronically 
powered non- invasive ventilators (Philips 
A30) were used to provide CPAP with wall 
oxygen entrained into the circuit as per NHS 
England guidelines.8 A non- vented mask 
or visor that covered the patient’s nose and 
mouth was used. HEPA viral filters were fitted 
to the expiratory port of the circuit. Medical 
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and nursing staff who were non- respiratory specialists 
completed CPAP competency training, with the respira-
tory team providing ward- based medical, physiotherapy 
and nursing care. Due to the rapid increase in critically 
ill patients being admitted with COVID-19, CPAP trials 
could not take place inside the critical care unit; however, 
the critical care team provided an outreach and oversight 
service. Patients were monitored frequently with three 
consultant led multidisciplinary board rounds taking 
place each day. Patients were eligible for a trial of CPAP 
if they were deemed appropriate for mechanical venti-
lation, had type 1 respiratory failure and did not have a 
standard contraindication to positive pressure. Patients 
were initially trialled with one hour of CPAP, with a 
starting CPAP of 5 cmH2O increasing to 10 cmH2O as 
needed based on respiratory rate, oxygen saturations and 
clinical assessment; arterial blood gases were only taken 
if clinically indicated. CPAP of more than 10 cmH2O was 
used, if required, after consultation with a respiratory or 
critical care consultant. Oxygen flow was titrated to main-
tain oxygen saturation of above 94%.
For the purposes of this service evaluation, we iden-
tified all patients undergoing CPAP on the infectious 
disease unit between 1 April and 30 April 2020. Data 
presented here were retrospectively extracted from 
patient records. Continuous variables are presented as 
medians and IQRs and categorical variables as propor-
tions. Analysis was done using Stata V.14.2 (StataCorp, 
V.14, 2015). As a service evaluation using anonymised 
and routinely collected patient data, informed consent 
and research and ethical committee approval were not 
required.
RESULTS
Twenty- four patients were treated with CPAP; all had 
type 1 respiratory failure, and all were deemed appro-
priate for intubation and invasive mechanical ventila-
tion (IMV) prior to a trial of CPAP. Clinical details and 
outcomes of CPAP are shown in table 1. The majority of 
patients (21/24 (88%)) were male, with a median age 
of 52 and median body mass index (BMI) of 31. The 
majority (23/24) had a clinical frailty score of two, one 
patient had a score of three. Prior to starting CPAP, 
all patients had some level of respiratory distress with 
a median P/F ratio of 122 mm Hg, significant oxygen 
requirements (median FiO2 0.77) and median respira-
tory rate was 33. All patients have now completed 
their episodes of care. Over half (14/24 (58%)) of the 
patients that received CPAP did not require intubation 
and IMV; of these, all have recovered sufficiently to be 
discharged home. Nine out of 24 (38%) patients failed 
CPAP and required critical care admission for IMV; all 
required intubation within 24 hours of initiating CPAP, 
with a median time to intubation of four hours (IQR 2–9 
hours). At the time of writing, five out of nine (56%) 
of those intubated have been successfully extubated 
and recovered, four (44%) have died. The median age 
of those that died was 60, with two out of four patients 
aged over 70, all four patients were male. Hypertension 
and diabetes or a cardiac history was recorded in two 
out of four patient’s medical history, with two patients 
having no significant medical history (including one 
patient under the age of 70). Overall, 19 out of 24 (79%) 
patients have survived to discharge. One out of 24 died 
having had CPAP without IMV as their clinical picture 
had changed while on CPAP and the decision to escalate 
was rescinded. There were no serious adverse incidents 
reported via our internal incident reporting mechanisms 
during this period related to CPAP.
Table 1 Demographics and CPAP outcome
Variable Value (IQR/%)
N 24
Demographics
Age 52 (46.5–60)
Male sex 21/24 (88%)
Median BMI (kg/m2)* 31 (27–33.5)
Comorbidities
Hypertension 8/24 (33%)
Diabetes 6/24 (25%)
Heart disease 3/24 (13%)
Other 8/24 (33%)
Smoking status
Current 1/23 (4%)
Ex 4/23 (17%)
Never 18/23 (79%)
Respiratory function prior to CPAP
Median FiO2 (%) 77 (45–100)
Median SpO2 on oxygen therapy (%) 93 (89–95.9)
Median RR 33 (28–40)
Median PF ratio (mm† Hg)† 122 (97–175)
CPAP settings (first hour)
Median starting CPAP (cmH2O) 8.75 (7.5–10)
Median starting oxygen on CPAP (L/min) 9 (6–15)
Outcomes
Weaned off CPAP and discharged 14/24 (58%)
Died on CPAP 1/24 (4%)
Intubated 9/24 (38%)
Median time on CPAP (days) 4.5 (2.5–5.5)
Median bed stay (days) 10.5 (7.5–11.5)
Median time to intubation (hours) 4 (2–9)
Died once IMV 4 (44.5%)
Weaned and Recovered once IMV 5 (55.5%)
*n=20.
†n=21.
BMI, body mass index; CPAP, continuous positive airway pressure 
; IMV, invasive mechanical ventilation.  o
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CONCLUSION
In the context of the COVID-19 pandemic, we were able 
to safely deploy CPAP on a rapidly repurposed ward with 
increased negative pressure capacity, outside a tradi-
tional critical care environment. Over half of patients 
treated successfully avoided mechanical ventilation and 
those who failed CPAP did so rapidly, usually within a few 
hours. Careful patient selection and close monitoring 
is crucial to ensure that those who are not improving 
on CPAP are identified early. Collaboration between 
respiratory and infectious disease staff and the installa-
tion of enhanced monitoring were key to ensuring that 
CPAP was delivered safely and those who required IMV 
received this in a timely manner. Due to the aerosol- 
generating nature of CPAP, concerns have been raised 
regarding the safety of its use in COVID-19. We ensured 
that CPAP was provided in negative pressure rooms with 
staff who had both the correct PPE and a high standard 
of training in how to use it. To date, there have been no 
cases of COVID-19 among nursing staff who looked after 
this cohort of patients.
In conclusion, our experience of a novel combined 
infectious disease and respiratory CPAP service for 
patients with COVID-19 outside of a critical care envi-
ronment for patients with type 1 respiratory failure 
has been positive. Our data suggest that, with careful 
patient selection and close monitoring, CPAP can be a 
successful treatment strategy in critically ill patients with 
type 1 respiratory failure in COVID-19, and that it can 
be safely deployed outside the critical care environment. 
We also believe that CPAP could be a valuable treatment 
option in lower resourced settings with limited capacity 
for mechanical ventilation, and note that it is included 
in the WHO COVID-19 clinical guidance.7 Nevertheless, 
we recognise that many questions remain; our study has 
a small sample size and is uncontrolled. Clinical trials are 
needed in order to guide clinical recommendations as to 
optimum timing of CPAP and selection of patients who 
are most likely to benefit. The role of CPAP in patients 
with significant comorbidities who are not deemed appro-
priate for invasive ventilation is uncertain and the relative 
merits of other non- invasive mechanisms of respiratory 
support such as high flow oxygen are unknown. We await 
the results of a randomised controlled trial to compare 
the effectiveness of CPAP, nasal high flow oxygen and 
standard wall oxygen in reducing mortality or the need 
for IMV in COVID-19.9 Until such time as robust data are 
available, our experiences suggest that CPAP has a role 
in the management of type 1 respiratory failure due to 
COVID-19.
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